Clinical Trial Update: Daylight-mediated Photodynamic Therapy of Actinic Keratoses:Comparing 0.2%HAL With 16%MAL [Phase 1, Phase 2]

View source ↗

Summary

This is a Phase 1/2 clinical trial comparing daylight-mediated photodynamic therapy using 0.2% hexyl aminolevulinate versus 16% methyl aminolevulinate for actin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Actinic Keratosis

Drugs mentioned

• Hexyl aminolevulinate (0.2%) daylight PDT (Hexyl aminolevulinate)
• Methyl aminolevulinate (16%) daylight PDT (Methyl aminolevulinate)

Snippet

Sponsor: Joint Authority for Päijät-Häme Social and Health Care | Conditions: Actinic Keratoses | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2016-07-11